Autoinduction as Means for Optimization of the Heterologous Expression of Recombinant Single-Chain Fv (scFv) Antibodies.
Autoinduction
Bacterial expression
Single-chain fragment variable (scFv)
Journal
Molecular biotechnology
ISSN: 1559-0305
Titre abrégé: Mol Biotechnol
Pays: Switzerland
ID NLM: 9423533
Informations de publication
Date de publication:
Nov 2021
Nov 2021
Historique:
received:
05
11
2020
accepted:
20
06
2021
pubmed:
4
7
2021
medline:
15
2
2022
entrez:
3
7
2021
Statut:
ppublish
Résumé
The monoclonal antibodies and the recombinant antibody fragments are widely used in the biotechnology studies and in medicine as a powerful therapeutic and diagnostic tool. The most commonly used recombinant antibody fragments are single-chain fragment variable (scFv) because of their small size and minimal immunogenicity while still retaining high-affinity antigen binding. A wide range of expression systems such as bacterial and eukaryotic cell systems enable the sufficient production of scFv antibodies. However, their stable expression in soluble form and correct protein folding are often insufficient. In the present study, we present the autoinduction as a key element of the optimized scheme for heterologous expression of human monoclonal scFv antibodies (clones A1 and A12) in Escherichia coli HB2151, which resulted in two-fold increase of the total protein yield in 24 h.
Identifiants
pubmed: 34215946
doi: 10.1007/s12033-021-00363-2
pii: 10.1007/s12033-021-00363-2
doi:
Substances chimiques
Antibodies, Monoclonal
0
Recombinant Proteins
0
Single-Chain Antibodies
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1049-1056Subventions
Organisme : Bulgarian National Science Fund
ID : Grant DN01/9
Informations de copyright
© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Références
Lu, R. M., Hwang, Y. C., Liu, I. J., Lee, C. C., Tsai, H. Z., Li, H. J., & Wu, H. C. (2020). Development of therapeutic antibodies for the treatment of diseases. Journal of Biomedical Science, 27(1), 1.
doi: 10.1186/s12929-019-0592-z
Shen, Z., Yan, H., Zhang, Y., Mernaugh, R. L., & Zeng, X. (2008). Engineering peptide linkers for scFv immunosensors. Analytical Chemistry, 80(6), 1910–1917.
doi: 10.1021/ac7018624
Ahmad, Z. A., Yeap, S. K., Ali, A. M., Ho, W. Y., Alitheen, N. B., & Hamid, M. (2012). scFv antibody: Principles and clinical application. Clinical and Developmental Immunology, 2012, 980250.
doi: 10.1155/2012/980250
Monnier, P. P., Vigouroux, R. J., & Tassew, N. G. (2013). In vivo applications of single chain Fv (variable domain) (scFv) fragments. Antibodies, 2, 193–208.
doi: 10.3390/antib2020193
Wu, C. H., Liu, I. J., Lu, R. M., & Wu, H. C. (2016). Advancement and applications of peptide phage display technology in biomedical science. Journal of Biomedical Science, 23, 8.
doi: 10.1186/s12929-016-0223-x
Almagro, J. C., Pedraza-Escalona, M., Arrieta, H. I., & Pérez-Tapia, S. M. (2019). Phage display libraries for antibody therapeutic discovery and development. Antibodies (Basel), 8(3), 44.
doi: 10.3390/antib8030044
Corchero, J. L., Gasser, B., Resina, D., Smith, W., Parrilli, E., Vázquez, F., Abasolo, I., Giuliani, M., Jäntti, J., Ferrer, P., Saloheimo, M., Mattanovich, D., Schwartz, S., Jr., Luisa Tutino, M., & Villaverde, A. (2013). Unconventional microbial systems for the cost-efficient production of high-quality protein therapeutics. Biotechnology Advances, 31(2), 140–153. https://doi.org/10.1016/j.biotechadv.2012.09.001
doi: 10.1016/j.biotechadv.2012.09.001
pubmed: 22985698
Frenzel, A., Hust, M., & Schirrmann, T. (2013). Expression of recombinant antibodies. Frontiers in Immunology, 4, 217.
doi: 10.3389/fimmu.2013.00217
Terpe, K. (2006). Overview of bacterial expression systems for heterologous protein production: From molecular and biochemical fundamentals to commercial systems. Applied Microbiology and Biotechnology, 72(2), 211–222.
doi: 10.1007/s00253-006-0465-8
Ni, Y., & Chen, R. (2009). Extracellular recombinant protein production from Escherichia coli. Biotechnology Letters, 31(11), 1661–1670.
doi: 10.1007/s10529-009-0077-3
Fernandes, J. C. (2018). Therapeutic application of antibody fragments in autoimmune diseases: Current state and prospects. Drug Discovery Today, 23, 1996–2002. https://doi.org/10.1016/j.drudis.2018.06.003
doi: 10.1016/j.drudis.2018.06.003
pubmed: 29890227
Baneyx, F., & Mujacic, M. (2004). Recombinant protein folding and misfolding in Escherichia coli. Nature Biotechnology, 22(11), 1399–1408.
doi: 10.1038/nbt1029
Burgess, R. R. (2009). Refolding solubilized inclusion body proteins. Methods in Enzymology, 463, 259–282.
doi: 10.1016/S0076-6879(09)63017-2
Deliyska, B., Tsacheva, I., Radanova, M., Stoianova, V., Tchorbadjieva, M., & Dobreva, N. (2007). Lupus nephritis sera contain autoantibodies that recognize epitopes within the globular fragment of C1q. Medicinski Pregled, 60(Suppl 2), 25–27.
pubmed: 18928152
Stoyanova, V., Tchorbadjieva, M., Deliyska, B., Vasilev, V., & Tsacheva, I. (2012). Biochemical analysis of the epitope specificities of anti-C1q autoantibodies accompanying human lupus nephritis reveals them as a dynamic population in the course of the disease. Immunology Letters, 148(1), 69–76. https://doi.org/10.1016/j.imlet.2012.08.007
doi: 10.1016/j.imlet.2012.08.007
pubmed: 22981967
Rangelov, M. A., Todorova, N. H., & Tsacheva, I. G. (2017). In silico investigation of single-chain variable fragment (scFv) antibody, structurally similar to native C1q globular heads. Bulgarian Chemical Communications, Special Issue E, 49, 50–53.
Studier, F. W. (2005). Protein production by autoinduction in high density shaking cultures. Protein Expression and Purification, 41(1), 207–234.
doi: 10.1016/j.pep.2005.01.016
Miller, K. D., Weaver-Feldhaus, J., Gray, S. A., Siegel, R. W., & Feldhaus, M. J. (2005). Production, purification, and characterization of human scFv antibodies expressed in Saccharomyces cerevisiae, Pichia pastoris, and Escherichia coli. Protein Expression and Purification, 42(2), 255–267.
doi: 10.1016/j.pep.2005.04.015
Chen, R. (2012). Bacterial expression systems for recombinant protein production E. coli and beyond. Biotechnology Advances, 30, 1102–1107.
doi: 10.1016/j.biotechadv.2011.09.013
Miethe, S., Meyer, T., Wöhl-Bruhn, S., Frenzel, A., Schirrmann, T., Dübel, S., & Hust, M. (2013). Production of single chain fragment variable (scFv) antibodies in Escherichia coli using the LEX™ bioreactor. Journal of Biotechnology, 163, 105–111.
doi: 10.1016/j.jbiotec.2012.07.011
Donev, V., & Tsacheva, I. (2019). Autoinduction of the expression of the recombinant forms of the three globular fragments constituting gC1 q. Comptes rendus de l’Academie bulgare des Sciences, 72(5), 622–626.
Martin, C. D., Rojas, G., Mitchell, J. N., Vincent, K. J., Wu, J., McCafferty, J., & Schofield, D. J. (2006). A simple vector system to improve performance and utilisation of recombinant antibodies. BMC Biotechnology, 6, 46.
doi: 10.1186/1472-6750-6-46
Carpenter, J. F., Manning, M. C., & Randolph, T. W. (2002). Long-term storage of proteins. Current Protocols in Protein Science, 27, 4.6.1–4.6.6. https://doi.org/10.1002/0471140864.ps0406s27
doi: 10.1002/0471140864.ps0406s27
Gil, D., & Schrum, A. G. (2013). Strategies to stabilize compact folding and minimize aggregation of antibody-based fragments. Advances in Bioscience and Biotechnology, 4(4a), 73–84.
doi: 10.4236/abb.2013.44A011
Mascarenhas, N. M., & Gosavi, S. (2017). Understanding protein domain-swapping using structure-based models of protein folding. Progress in Biophysics and Molecular Biology, 128, 113–120.
doi: 10.1016/j.pbiomolbio.2016.09.013